Montelukast as an Adjunct to Oral and Inhaled Steroid Therapy in Chronic Nasal Polyposis
| Autor: | Rosemary A. Stewart, Bhaskar Ram, John M. Weiner, Garun S. Hamilton, Kevin J. Kane |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Cyclopropanes Male medicine.medical_specialty Prednisolone medicine.medical_treatment Administration Oral Acetates Sulfides Gastroenterology law.invention Cohort Studies 03 medical and health sciences Nasal Polyps 0302 clinical medicine Pharmacotherapy Randomized controlled trial law Internal medicine Administration Inhalation Humans Medicine Nasal polyps Budesonide 030223 otorhinolaryngology Glucocorticoids Montelukast Aged Aged 80 and over Inhalation business.industry Leukotriene receptor Middle Aged medicine.disease Treatment Outcome Otorhinolaryngology Nasal spray 030220 oncology & carcinogenesis Anesthesia Quinolines Leukotriene Antagonists Drug Therapy Combination Female Surgery business medicine.drug Cohort study |
| Zdroj: | Otolaryngology–Head and Neck Surgery. 139:682-687 |
| ISSN: | 1097-6817 0194-5998 |
| DOI: | 10.1016/j.otohns.2008.07.010 |
| Popis: | Objective To examine the potential of montelukast, a leukotriene receptor antagonist, as an adjunct to oral and inhaled steroid in subjects with chronic nasal polyps. Study Design Prospective, randomized controlled trial. Subjects and Methods Thirty-eight consecutive adult patients with bilateral nasal polyps were randomized into two groups. Eighteen subjects were treated with oral prednisolone for 14 days and budenoside nasal spray for 8 weeks. Twenty subjects received similar treatment with additional oral montelukast for 8 weeks. Subjects completed a modified nasal ICSD symptom score at 8 and 12 weeks after beginning treatment and the SF-36 quality of life questionnaire at 12 weeks. Results Symptom scores improved in both groups after treatment. Subjects treated with montelukast reported significantly less headache (P = 0.013), facial pain (P = 0.048) and sneezing (P = 0.03) than controls. Four weeks after completing treatment, no significant differences were recorded. Conclusion Montelukast therapy may have clinical benefit as an adjunct to oral and inhaled steroid in chronic nasal polyposis, but effects are not maintained after cessation of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text